Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose midazolam vs etomidate pre-treatment to prevent myoclonic movements after etomidate
IRCT20160307026950N6Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of midazolam in myoclonus (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Incidence of myoclonic movements after etomidate injection. Started Jun 2017; status: completed.
02
Drugs
midazolam
03
Conditions
myoclonus
Beyond the preview
Go deeper on IRCT20160307026950N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160307026950N6.